Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8783850 | 1.00 | HIF1A (0.53) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL17892148 | 0.86 | CYP1A2 (0.44) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL1081535 | 0.85 | CYP1A2 (0.47) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL1712450 | 0.81 | CYP1A2 (0.47) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL1712451 | 0.81 | CYP1A2 (0.47) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL1712531 | 0.81 | CYP1A2 (0.47) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL637562 | 0.80 | HIF1A (0.59) | HIF1ACYP2C19CYP1A2KMT2ACYP2D6 | |
| SCHEMBL27477585 | 0.80 | CYP2C19 (0.50) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL305912 | 0.79 | CYP1A2 (0.70) | HIF1ACYP2C19CYP1A2KMT2AMEN1 | |
| SCHEMBL2089245 | 0.79 | CYP1A2 (0.70) | HIF1ACYP2C19CYP1A2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-1015008-B1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140005106-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2409569-A2 | Method for administering GLP-1 molecules | Emisphere Technologies, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-5876710-A | DRUG DELIVERY; USING A BROMINATED BENZAMIDE COMPOUND | EMISPHERE TECHNOLOGIES INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5804688-A | 6-N-(3,5-DICHLORO-2-HYDROXYBENZOYL)AMINOCAPROIC ACID | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| WO-1998034632-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| US-5776888-A | 3-(DIMETHOXYBENZOYLAMINOPHENYL) PROPIONIC ACID | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5773647-A | USING A AROMATIC COMPOUND CONTAINING AMIDE AND CARBOXY GROUPS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5583020-A | IONIZATION; DRUG DELIVERY | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| CN-1137287-A | Liquid laundry detergents containing polyamino acid and polyalkylene glycol | PROCTER & GAMBLE (US) | 1996-12-04 | — | — | CN | disclosed |
| EP-0669926-A1 | PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012516-A9 | PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS | — | 1994-08-04 | — | — | WO | disclosed |
| WO-1994012516-A1 | PERMEABILITY ENHANCERS FOR IONIC THERAPEUTIC POLYMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | HIF1A 1478/4885CYP2C19 1075/4885CYP1A2 2415/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | HIF1A 1478/4885CYP2C19 1075/4885CYP1A2 2415/4885 |
| US-20140005106-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | HIF1A 1478/4885CYP2C19 1075/4885CYP1A2 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.